XML 20 R9.htm IDEA: XBRL DOCUMENT v3.25.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2025
Fair Value Measurements  
Fair Value Measurements

(4)  Fair Value Measurements

The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

As of

​

​

​

​

​

​

​

​

​

​

    

September 30, 2025

    

Level 1

    

Level 2

    

Level 3

​

​

(In thousands)

Assets:

​

​

​

​

​

​

​

​

​

​

​

​

Money market funds and cash equivalents

​

$

23,935

​

​

—

​

$

23,935

​

​

—

Marketable securities

​

​

547,186

​

​

—

​

​

547,186

​

​

—

​

​

$

571,121

​

​

—

​

$

571,121

​

​

—

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

As of

​

​

​

​

​

​

​

​

​

​

    

December 31, 2024

    

Level 1

    

Level 2

    

Level 3

​

​

(In thousands)

Assets:

​

​

​

​

​

​

​

​

​

​

​

​

Money market funds and cash equivalents

​

$

9,927

​

​

—

​

$

9,927

​

​

—

Marketable securities

​

​

696,925

​

​

—

​

​

696,925

​

​

—

​

​

$

706,852

​

​

—

​

$

706,852

​

​

—

​

The Company’s financial assets consist mainly of money market funds, cash equivalents and marketable securities and are classified as Level 2 within the valuation hierarchy. The Company values its marketable securities utilizing independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources.

Contingent consideration liabilities measured at fair value using Level 3 inputs were $0.0 million as of September 30, 2025 and December 31, 2024. The valuation technique used to measure fair value of the Company’s Level 3 liabilities, which consist of contingent consideration related to the acquisition of Kolltan Pharmaceuticals, Inc. (“Kolltan”) in 2016, is primarily an income approach. The significant unobservable inputs used in the fair value measurement of the contingent consideration are estimates including probability of success, discount rates and amount of time until the conditions of the milestone payments are met.

There was no gain or loss on fair value remeasurement of contingent consideration recorded during the three and nine months ended September 30, 2025 or September 30, 2024. The assumptions related to determining the fair value of contingent consideration include a significant amount of judgment, and any changes in the underlying estimates could have a material impact on the amount of contingent consideration adjustment recorded in any given period.

The Company did not have any transfers in or out of Level 3 assets or liabilities during the nine months ended September 30, 2025 or September 30, 2024.